Avanos Merger 8-K: $25 a Share Cash Deal With AIP-Backed Buyer

The news

Avanos Medical, Inc. disclosed in a merger 8-K filed April 14, 2026, that it had agreed to be acquired for $25.00 per share in cash. The agreement, dated April 13, was signed with A-AV Holdco I, Inc. and its subsidiary A-AV MergerSub, Inc., acquisition vehicles backed by an equity commitment from American Industrial Partners Capital Fund VIII, L.P.

Under the structure described in Item 1.01, the merger subsidiary will merge into Avanos, which will survive as a wholly owned subsidiary of the buyer. Outstanding restricted stock units and options will be converted into cash payments according to their vesting terms.

Closing conditions include approval by a majority of Avanos stockholders, expiration or termination of the waiting period under the Hart-Scott-Rodino Act, the absence of legal restraints, the accuracy of representations and warranties, and no material adverse effect on the company. The agreement contemplates closing on or before January 13, 2027. Avanos would owe a $37.5 million termination fee if it ends the deal to accept a superior proposal. The filing states the board unanimously recommended that stockholders approve the merger and that the deal is not conditioned on financing.

Our analysis

The merger 8-K reads like a conventional private equity take-private, and its key protections are what one would expect. The equity commitment from an AIP fund, paired with the absence of a financing condition, shifts funding risk away from Avanos stockholders: if the buyer’s lenders falter, the sponsor’s commitment is meant to fill the gap.

The termination fee is the clearest signal of how open the door remains to a rival bid. A $37.5 million fee is a fixed cost any competing bidder would need to cover on top of a higher price. Without the company’s share count in this filing, we cannot express the fee as a percentage of equity value, but the dollar amount gives interested parties a precise hurdle.

The outside date nine months after signing is also telling. That is a relatively generous window for a deal requiring only HSR clearance and a stockholder vote, and it gives the parties room if antitrust review or the proxy process takes longer than planned.

The equity award treatment is also standard but worth noting. Converting restricted stock units and options into cash payments tied to their vesting schedules keeps employees’ incentives aligned with completing the deal while avoiding a large upfront payout to unvested holders.

For stockholders, the essential question is whether $25 in cash reflects fair value for a medical device company that chose to sell rather than continue as a standalone public business. The proxy statement, which will contain the background of the merger and the financial advisers’ fairness analyses, is where that question will be answered in detail.

Room for disagreement

One reading is that a fully financed, sponsor-backed cash deal with no financing condition is a strong outcome for holders who want certainty. Another is that a take-private by an industrial-focused private equity firm signals the buyer sees value that public markets were not crediting, and that stockholders are handing over that upside. The board’s unanimous recommendation supports the first view, but activist investors in similar situations have sometimes argued the second and pressed for a higher price or a market check.

There is also a question about the go-shop or no-shop terms. Item 1.01 describes a termination right for a superior proposal, but the strength of the restrictions on soliciting other bids will matter to how realistic a competing offer is.

What to watch

Watch for the preliminary proxy statement and its description of the sale process, any Schedule 13D filings from holders who oppose the price, the HSR waiting period, the date of the stockholder vote, and whether any competing proposal emerges before the meeting. Closing is required on or before January 13, 2027.